Why do we need PrEP Guidelines? Ask an expert. VIDEO
Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…
Site search
Global: All items in all
629 results
| 1 Global
Welcome to the new CTN website
Welcome to the new CTN website. We’ve updated our design to current web standards with a responsive, mobile-friendly theme that makes it easier to navigate whether you’re on a desktop or a mobile device.
Vision
The CTN - An innovative partnership Over 300 studies reviewed Over 20,000 participants since 1990 Over 140 Investigators Over 130...Vicriviroc in HIV treatment-experienced people
Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects.
Turning to PrEP for Prevention
The approval of Truvada as PrEP marks a turning point in HIV prevention in Canada – if all goes as planned
Troy Grennan on the novel mRNA-based HPV testing: CTNPT 023
TriiAdd study looks to improve adherence with a single pill per day
The TriiAdd study (CTN 286) will test to see if using a new single tablet regimen called Triumeq combined with adherence counseling support can improve adherence and virologic suppression for people living with HIV.
Trial Results
Results of clinical trials are presented at scientific conferences and/or published in peer-reviewed papers. The list below refers to summaries...Treatment Guidelines
Canadian Guidelines on HIV Pre-exposure Prophylaxis and Non-Occupational Post Exposure Prophylaxis: Darrell H. S. Tan, Mark W. Hull, Deborah Yoong,…
Treatment Guidelines
Treatment Access Issues Dominate HIV/Viral Hepatitis Co-infection Meeting
Treatment access issues related to HCV infection and HIV-HCV co-infection dominated much of the content at the 2nd International HIV/Viral Hepatitis Co-infection Meeting that took place from July 17-18, 2015 before the larger IAS 2015 conference in Vancouver.
